Reckitt Benckiser's $1.4bn settlement over Suboxone verges on the farcical | Nils Pratley

The UK company may have avoided a day in court, but its claims
of innocence will never be tested

One can say it is entirely logical for the board of Reckitt
Benckiser to
write a cheque for $1.4bn
(£1.1bn) to end US authorities’
investigation into how opioid treatment Suboxone Film was marketed
by a former subsidiary. One can also call the outcome
ridiculous.

The logical aspect lies in the commercial opportunity to make a
serious legal headache go away with no admission of wrongful
conduct. Fighting the US Department of Justice (DoJ) and Federal
Trade Commission (FTC) in front of a jury would be a high-risk
strategy for a UK company, especially against the backdrop of an
opioid crisis in the US that has claimed 200,000 lives. The detail
that Suboxone was meant to be treating addiction could become lost
in the anger.

Source: FS – All-News2-Economy
Reckitt Benckiser's .4bn settlement over Suboxone verges on the farcical | Nils Pratley